Immunome (IMNM) Common Equity (2023 - 2025)
Historic Common Equity for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $263.9 million.
- Immunome's Common Equity rose 2280.67% to $263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.9 million, marking a year-over-year increase of 2280.67%. This contributed to the annual value of $181.2 million for FY2024, which is 5111.94% up from last year.
- Per Immunome's latest filing, its Common Equity stood at $263.9 million for Q3 2025, which was up 2280.67% from $269.3 million recorded in Q2 2025.
- Immunome's 5-year Common Equity high stood at $307.1 million for Q1 2025, and its period low was $6.1 million during Q3 2023.
- For the 3-year period, Immunome's Common Equity averaged around $175.0 million, with its median value being $214.9 million (2024).
- In the last 5 years, Immunome's Common Equity skyrocketed by 343696.51% in 2024 and then surged by 607.95% in 2025.
- Over the past 3 years, Immunome's Common Equity (Quarter) stood at $119.9 million in 2023, then soared by 51.12% to $181.2 million in 2024, then skyrocketed by 45.68% to $263.9 million in 2025.
- Its last three reported values are $263.9 million in Q3 2025, $269.3 million for Q2 2025, and $307.1 million during Q1 2025.